<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82753">
  <stage>Registered</stage>
  <submitdate>11/04/2008</submitdate>
  <approvaldate>14/04/2008</approvaldate>
  <actrnumber>ACTRN12608000200381</actrnumber>
  <trial_identification>
    <studytitle>Effects of early luteal phase vaginal progesterone supplementation on the outcome of in-vitro fertilization and embryo transfer</studytitle>
    <scientifictitle>Effects of early luteal phase vaginal progesterone supplementation on the outcome of in-vitro fertilization and embryo transfer</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>infertility</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fertility including in vitro fertilisation</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Vaginal progesterone supplementation in early luteal phase after the treatment of in-vitro fertilization and embryo transfer (a total of nine doses of 200 mg micronized progesterone vaginally, three times daily commencing in the afternoon of oocyte retrieval till the morning of embryo transfer)</interventions>
    <comparator>No vaginal pregesterone supplementation  apart from the standard HCG (human chorionic gonadotrophin) luteal phase support</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>pregnancy rates of the treatment of in-vitro fertilization and embryo transfer</outcome>
      <timepoint>ten days after the last dose of HCG luteal phase support</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>implantation rates of the treatment of in-vitro fertilization and embryo transfer</outcome>
      <timepoint>two weeks after positive pregnancy test of the treatment of in-vitro fertilization and embryo transfer</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>The difference in serum progesterone concentrations before and after the intervention (Serum progesterone level was quantified by using a competitive immunoassay with direct chemiluminesent technology)</outcome>
      <timepoint>on the day of ovulatory dose of HCG and the day of embryo transfer</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>women undergoing the treatment of in-vitro fertilization and embryo transfer, with HCG administration as the standard luteal phase support</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>39</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>age = 40 year-old
use of vaginal progesterone for luteal phase support because of risk of ovarian hyperstimulation syndrome
distorted uterine cavity, e.g. due to submucosal fibroids or uterine anomalies</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Informed consent was sought from potential participants on the day of ovulatory dose of HCG. The randomization was performed by computer-generated program. Sealed opaque envelopes were used for allocation.  When the use of HCG administration as the standard luteal phase support had been confirmed after oocyte retrieval, the participants were randomly allocated into either the study group or the control group on one-to-one basis.</concealment>
    <sequence>The randomization was performed by computer-generated program on one-to-one basis.</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>1/01/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>196</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>The Chinese University of Hong Kong</primarysponsorname>
    <primarysponsoraddress>Department of Obstetrics &amp; Gynaecology
Prince of Wales Hospital
The Chinese University of Hong Kong
Shatin, Hong Kong S.A.R.</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>The Chinese University of Hong Kong</fundingname>
      <fundingaddress>Department of Obstetrics &amp; Gynaecology
Prince of Wales Hospital
The Chinese University of Hong Kong
Shatin, Hong Kong S.A.R.</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>The Chinese University of Hong Kong</sponsorname>
      <sponsoraddress>Department of Obstetrics &amp; Gynaecology
Prince of Wales Hospital
The Chinese University of Hong Kong
Shatin, Hong Kong S.A.R.</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Chinese University of Hong Kong</ethicname>
      <ethicaddress>The Chinese University of Hong Kong
Shatin, Hong Kong S.A.R.</ethicaddress>
      <ethicapprovaldate>12/12/2008</ethicapprovaldate>
      <hrec>CRE-2001.381</hrec>
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Po-mui LAM</name>
      <address>Department of Obstetrics &amp; Gynaecology
Prince of Wales Hospital
The Chinese University of Hong Kong
Shatin, Hong Kong S.A.R.</address>
      <phone>852 2632 2810</phone>
      <fax>852 2636 0008</fax>
      <email>lampomui@cuhk.edu.hk</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Po-mui LAM</name>
      <address>Department of Obstetrics &amp; Gynaecology
Prince of Wales Hospital
The Chinese University of Hong Kong
Shatin, Hong Kong S.A.R.</address>
      <phone>852 2632 2810</phone>
      <fax>852 2636 0008</fax>
      <email>lampomui@cuhk.edu.hk</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Po-mui LAM</name>
      <address>Department of Obstetrics &amp; Gynaecology
Prince of Wales Hospital
The Chinese University of Hong Kong
Shatin, Hong Kong S.A.R.</address>
      <phone>852 2632 2810</phone>
      <fax>852 2636 0008</fax>
      <email>lampomui@cuhk.edu.hk</email>
      <country>China</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>